Insmed Incorporated (INSM) Stock
INSM Key Statistics
About Insmed Incorporated
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
CEO: William H. Lewis. Company website
INSM — Frequently Asked Questions
What is the INSM stock price today?
Insmed Incorporated (INSM) trades at $120.75, up 1.05% on the day, as of Nov 12, 2026 09:31 UTC.
What is Insmed Incorporated's market cap?
Insmed Incorporated has a market capitalisation of $26.49B, calculated from the live INSM share price and shares outstanding.
What is the P/E ratio of INSM?
INSM has no meaningful price-to-earnings ratio: Insmed Incorporated lost $2.81 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Insmed Incorporated make?
Insmed Incorporated generated revenue of $1.52B over the trailing twelve months, which puts the stock at 17.43 times sales.
What is the 52-week range for INSM?
INSM has traded between $90.39 and $212.75 over the past 52 weeks, and the last price is 43.2% below that high.
Is Insmed Incorporated profitable?
No. Insmed Incorporated is loss-making, with a net margin of -39.85% over the trailing twelve months.
What is the analyst price target for INSM?
Wall Street analysts rate INSM Buy, with an average price target of $191.06, 58.2% above the current price.
What sector is Insmed Incorporated in?
Insmed Incorporated is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Insmed Incorporated?
William H. Lewis is the chief executive of Insmed Incorporated, which employs 1,664 people.
Where can I track INSM in real time?
QFI Terminal shows INSM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See INSM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open INSM in Terminal See plans